Treatment of blastic plasmacytoid dendritic cell neoplasms with cord blood transplants

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 7, 2011, Pages 569-570

  Krishnan, Sathish ^a   Tan, Daryl ^a   Hwang, William Y K ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER REGRESSION; CANCER SURVIVAL; CHEMORADIOTHERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELLS; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; TRANSPLANTATION CONDITIONING;

EID: 80052396106     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005;153:874-880.
2. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+) CD56(+) malignancies. Blood. 2002;99:1556-1563.
3. Liang X, Graham DK. Natural killer cell neoplasms. Cancer. 2008;112:1425-1436.
4. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127:687-700.
5. Duff JM, Rossi ML, Fromm J, Hsu JW. A 21-year-old woman with blastic NK cell leukemia/lymphoma who achieved durable remission with hyperCVAD and unrelated umbilical cord blood transplant. Clin Adv Hem Oncol. 2011;9:566-568.
6. Yoshimasu T, Manabe A, Tanaka R, et al. Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. Bone Marrow Transplant. 2002;30:41-44.
7. Hirai M, Kadowaki N, Kitawaki T, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Tolllike receptors and endoplasmic reticulum homeostasis. Blood. 2011;117:500-509.
8. Reimer P, Rüdiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637-646.
9. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162:74-79.
10. Hwang WYK, Samuel M, Tan D, et al. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2007;13:444-453.
11. Dietrich S, Hegenbart U, Andrulis M, et al. Blastic plasmacytoid dendritic cell neoplasia (bpdc) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011; Epub ahead of print.